Sees Q1 revenue up 7.5%-9.5%, consensus $3.67B. The company said, “The company estimates net sales growth for the first quarter of 2024, versus the prior year period, to be in a range of approximately 7.5 to 9.5 percent on a reported basis, and approximately 7 to 9 percent on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.29 to $0.31 and estimates adjusted EPS, excluding certain charges (credits), of $0.50 to $0.52.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Boston Scientific call volume above normal and directionally bullish
- BSX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Boston Scientific price target raised to $70 from $62 at Wells Fargo
- Boston Scientific price target raised to $72 from $62 at Piper Sandler
- Boston Scientific named 2024 Top Pick in MedTech at RBC Capital